Pitfalls of Commercially Available HPV Tests in HPV68a Detection

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Aug 6

PMID 31381580

Citations 2

Authors

Hana Jaworek

Katerina Kubanova

Vladimira Koudelakova

Rastislav Slavkovsky

Jiri Drabek

Marian Hajduch

Affiliations

Soon will be listed here.

Abstract

Background: Human papillomavirus 68 (HPV68) is a probable carcinogenic HPV genotype which is included in almost all HPV screening assays and exists as two genetically variable subtypes (HPV68a and HPV68b). Routine HPV sample testing has shown that the cobas 4800 HPV Test (Roche) provides higher false-negative rates for HPV68 status than PapilloCheck HPV-Screening (Greiner Bio-One). The aim of our study was to evaluate the efficacy of cobas 4800 in HPV68 detection.

Methods: A total of 2,145 cervical/cervicovaginal samples from women aged 17-88 were tested for HPV68 status using the cobas 4800 and PapilloCheck HPV tests. Viral load was assessed by quantitative PCR in all of the HPV68-positive cases. HPV68a/b subtyping was performed with real-time PCR followed by high resolution melting curve analysis, and was subsequently confirmed by Sanger sequencing.

Results: Cobas 4800 detected HPV positivity in only 13/33 HPV68 single-genotype infection cases. Viral load was comparable across both tested subgroups. HRM analysis and Sanger sequencing identified the HPV68a subtype in all of the 20 instances of cobas 4800 false negatives. HPV68a and HPV68b were detected in 3/13 and 10/13 cases identified as other HPV-positive by cobas 4800.

Conclusion: The HPV68a subtype was missed by cobas 4800 in more than 85% of all HPV68a-positive cases. Therefore, commercially available assays may underestimate HPV68 prevalence.

Citing Articles

Human Papillomavirus E7 and p16 mRNA Multiplexed Quantification by a QuantiGene Proof-of-Concept Assay Sensitively Detects Infection and Cervical Dysplasia Severity.

Skof A, Rotenberg L, Hannemann P, Thies S, Boschetti-Grutzmacher E, Kaufmann A Diagnostics (Basel). 2023; 13(6).

PMID: 36980443 PMC: 10047034. DOI: 10.3390/diagnostics13061135.

Novel concepts in cervical cancer screening: a comparison of VIA, HPV DNA test and p16/Ki-67 dual stain cytology in Western Kenya.

Orango E, Were E, Rode O, Muthoka K, Byczkowski M, Sartor H Infect Agent Cancer. 2020; 15:57.

PMID: 33024449 PMC: 7531147. DOI: 10.1186/s13027-020-00323-6.

References

Munoz N, Bosch F, de Sanjose S, Herrero R, Castellsague X, Shah K . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6):518-27. DOI: 10.1056/NEJMoa021641. View

Schiffman M, Khan M, Solomon D, Herrero R, Wacholder S, Hildesheim A . A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005; 97(2):147-50. DOI: 10.1093/jnci/dji014. View

Koressaar T, Remm M . Enhancements and modifications of primer design program Primer3. Bioinformatics. 2007; 23(10):1289-91. DOI: 10.1093/bioinformatics/btm091. View

Bosch F, Burchell A, Schiffman M, Giuliano A, de Sanjose S, Bruni L . Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008; 26 Suppl 10:K1-16. DOI: 10.1016/j.vaccine.2008.05.064. View

Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F . A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009; 10(4):321-2. DOI: 10.1016/s1470-2045(09)70096-8. View

Eklund C, Zhou T, Dillner J . Global proficiency study of human papillomavirus genotyping. J Clin Microbiol. 2010; 48(11):4147-55. PMC: 3020877. DOI: 10.1128/JCM.00918-10. View

de Sanjose S, Quint W, Alemany L, Geraets D, Klaustermeier J, Lloveras B . Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11):1048-56. DOI: 10.1016/S1470-2045(10)70230-8. View

Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S . Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012; 131(10):2349-59. DOI: 10.1002/ijc.27485. View

Van de Velde N, Boily M, Drolet M, Franco E, Mayrand M, Kliewer E . Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst. 2012; 104(22):1712-23. DOI: 10.1093/jnci/djs395. View

10.

. Biological agents. IARC Monogr Eval Carcinog Risks Hum. 2012; 100(Pt B):1-441. PMC: 4781184. View

11.

Rao A, Young S, Erlich H, Boyle S, Krevolin M, Sun R . Development and characterization of the cobas human papillomavirus test. J Clin Microbiol. 2013; 51(5):1478-84. PMC: 3647918. DOI: 10.1128/JCM.03386-12. View

12.

Dwight Z, Palais R, Kent J, Wittwer C . Heterozygote PCR product melting curve prediction. Hum Mutat. 2013; 35(3):278-82. DOI: 10.1002/humu.22494. View

13.

Eklund C, Forslund O, Wallin K, Dillner J . Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study. J Clin Microbiol. 2014; 52(2):449-59. PMC: 3911320. DOI: 10.1128/JCM.02453-13. View

14.

Kim N, Kang M, Lee S, Kim H, An J, Chung D . Uncommon and rare human papillomavirus genotypes relating to cervical carcinomas. Korean J Pathol. 2014; 48(1):43-9. PMC: 3950234. DOI: 10.4132/KoreanJPathol.2014.48.1.43. View

15.

Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch F . Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol. 2014; 234(4):441-51. DOI: 10.1002/path.4405. View

16.

Estrade C, Sahli R . Updating the PGMY primers and probes for improved detection of HPV68a: validation of version 2 of the PGMY-CHUV assay. J Clin Microbiol. 2014; 52(11):4033-5. PMC: 4313245. DOI: 10.1128/JCM.01950-14. View

17.

Monsonego J, Cox J, Behrens C, Sandri M, Franco E, Yap P . Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial. Gynecol Oncol. 2015; 137(1):47-54. DOI: 10.1016/j.ygyno.2015.01.551. View

18.

Batista J, Saddi V, Almeida de Carvalho K, Ribeiro A, Segati K, Carneiro M . Human papillomavirus genotypes 68 and 58 are the most prevalent genotypes in women from quilombo communities in the state of Maranhão, Brazil. Int J Infect Dis. 2017; 55:51-55. DOI: 10.1016/j.ijid.2017.01.001. View

19.

Xu L, Ostrbenk A, Poljak M, Arbyn M . Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework. J Clin Virol. 2017; 98:37-42. DOI: 10.1016/j.jcv.2017.12.001. View

20.

Nascimento M, Vidal F, Silva M, Batista J, Barbosa M, Filho W . Prevalence of human papillomavirus infection among women from quilombo communities in northeastern Brazil. BMC Womens Health. 2018; 18(1):1. PMC: 5748955. DOI: 10.1186/s12905-017-0499-3. View